Lymphoid leukemia
MONDO:0005402A malignant lymphocytic neoplasm of B-cell or T-cell lineage involving primarily the bone marrow and the peripheral blood. This category includes precursor or acute lymphoblastic leukemias and chronic leukemias.
Also known as: leukemia, LYMPHOCYTIC, malignant, lymphocytic leukemia, lymphogenous leukaemia, lymphogenous leukemia, lymphoid leukaemia (disease), lymphoid leukemia, lymphoid leukemia (disease), subacute lymphoid leukaemia
3180 clinical trials for this condition and its sub-types, 23 tagged with Lymphoid leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Lymphoid leukemia
-
Acute lymphoblastic leukemia 507 trials · 1,317 incl. sub-types
12 sub-types
- B-cell chronic lymphocytic leukemia 509 trials · 538 incl. sub-types Sub-types →
- B-cell acute lymphoblastic leukemia 244 trials · 258 incl. sub-types Sub-types →
- Childhood acute lymphoblastic leukemia 96 trials · 136 incl. sub-types Sub-types →
- Precursor B-cell acute lymphoblastic leukemia 66 trials · 111 incl. sub-types Sub-types →
- T-cell acute lymphoblastic leukemia 75 trials · 104 incl. sub-types Sub-types →
- Acute biphenotypic leukemia 88 trials · 91 incl. sub-types Sub-types →
- Adult acute lymphoblastic leukemia 43 trials · 54 incl. sub-types Sub-types →
- Prolymphocytic leukemia 20 trials · 38 incl. sub-types Sub-types →
- Plasma cell leukemia 32 trials
- Lymphoblastic leukemia, acute, with lymphomatous features 7 trials
- Precursor T-cell acute lymphoblastic leukemia 4 trials
- Null-cell leukemia 0 trials
-
T-cell leukemia 9 trials · 137 incl. sub-types
3 sub-types
- T-cell acute lymphoblastic leukemia 75 trials · 104 incl. sub-types Sub-types →
- Adult T-cell leukemia/lymphoma 31 trials
- T-cell adult acute lymphocytic leukemia 3 trials
Most studied deeper sub-types
-
Lower drug dose after transplant may cut infections without losing protection
Disease control OngoingThis study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Engineered immune cells take on tough childhood leukemia in new trial
Disease control OngoingThis study tests a new treatment called SJCAR19 for children and young adults up to age 21 whose B-cell acute lymphoblastic leukemia (ALL) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are collected, modified in a lab…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Experimental combo therapy aims to outsmart leukemia without dangerous side effects
Disease control OngoingThis early-stage trial tests whether giving specially engineered donor immune cells (CAR T cells) along with a special stem cell transplant (Orca-T) is safe for adults with a high-risk type of leukemia called B-cell ALL. The approach is designed to help the donor cells attack the…
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment made from a patient's own immune cells, which are genetically modified to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. The main goals…
Phase 1/2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…
Phase 1/2 • Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for older leukemia patients: targeted pill shows promise
Disease control OngoingThis phase II study tests a daily pill called PCI-32765 (ibrutinib) in 86 people with chronic lymphocytic leukemia or small lymphocytic lymphoma who are over 65 or have a specific genetic change (17p deletion). These groups often do not respond well to standard chemotherapy. Part…
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for blood cancer patients: using mismatched donors for transplants
Disease control OngoingThis study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New tool aims to improve care for older cancer patients
Knowledge-focused OngoingThis pilot study tests a new assessment tool called IA3-CP for cancer patients aged 65 and older. The tool gathers information on aging-related issues, mental health, health behaviors, and social factors to help doctors provide better, more personalized care. 35 participants are …
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:59 UTC